Free Trial
NASDAQ:GNLX

Genelux (GNLX) Stock Price, News & Analysis

Genelux logo
$2.96 -0.04 (-1.33%)
(As of 11/12/2024 ET)

About Genelux Stock (NASDAQ:GNLX)

Key Stats

Today's Range
$2.87
$2.99
50-Day Range
$1.98
$3.33
52-Week Range
$1.60
$16.60
Volume
84,026 shs
Average Volume
179,946 shs
Market Capitalization
$102.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.75
Consensus Rating
Buy

Company Overview

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Genelux Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
35th Percentile Overall Score

GNLX MarketRank™: 

Genelux scored higher than 35% of companies evaluated by MarketBeat, and ranked 691st out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genelux has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genelux has only been the subject of 4 research reports in the past 90 days.

  • Read more about Genelux's stock forecast and price target.
  • Earnings Growth

    Earnings for Genelux are expected to decrease in the coming year, from ($0.89) to ($1.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genelux is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genelux is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Genelux has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Genelux's valuation and earnings.
  • Percentage of Shares Shorted

    5.15% of the float of Genelux has been sold short.
  • Short Interest Ratio / Days to Cover

    Genelux has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Genelux has recently increased by 37.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Genelux does not currently pay a dividend.

  • Dividend Growth

    Genelux does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.15% of the float of Genelux has been sold short.
  • Short Interest Ratio / Days to Cover

    Genelux has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Genelux has recently increased by 37.50%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Genelux has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Genelux this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for GNLX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $736,831.00 in company stock.

  • Percentage Held by Insiders

    Only 9.30% of the stock of Genelux is held by insiders.

  • Percentage Held by Institutions

    Only 37.33% of the stock of Genelux is held by institutions.

  • Read more about Genelux's insider trading history.
Receive GNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter.

GNLX Stock News Headlines

Genelux Corp. Releases New Corporate Presentation
“This Changes Everything” - Trump Hands Millions Massive IRS Gift
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
Genelux (NASDAQ:GNLX) Now Covered by Analysts at Guggenheim
Genelux initiated with a Buy at Guggenheim
See More Headlines

GNLX Stock Analysis - Frequently Asked Questions

Genelux's stock was trading at $14.01 on January 1st, 2024. Since then, GNLX stock has decreased by 78.9% and is now trading at $2.96.
View the best growth stocks for 2024 here
.

Genelux Co. (NASDAQ:GNLX) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03.

Genelux (GNLX) raised $16 million in an initial public offering (IPO) on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

Top institutional shareholders of Genelux include LifeSteps Financial Inc. (0.23%), Exchange Traded Concepts LLC (0.19%) and Miracle Mile Advisors LLC (0.12%). Insiders that own company stock include Aladar Szalay, John Thomas, Sean Ryder, Caroline Jewett, Thomas Zindrick, Yong Yu, John W Smither, Joseph Cappello, Doug Samuelson and Qian Zhang.
View institutional ownership trends
.

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genelux investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/14/2024
Today
11/12/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNLX
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.75
High Stock Price Target
$32.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+533.4%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-28,300,000.00
Pretax Margin
-331,724.97%

Debt

Sales & Book Value

Annual Sales
$8,000.00
Price / Sales
12,777.95
Book Value
$0.73 per share

Miscellaneous

Free Float
31,323,000
Market Cap
$102.22 million
Optionable
Not Optionable
Beta
-1.85
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:GNLX) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners